Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action.
Mesenchymal stem cells (MSC) are potent in immunomodulation. It has been proven that MSC functioned to correct immune disorder in several immune diseases. Here, we tested the hypothesis that MSC from human bone marrow (hMSC) can provide a potential therapy for experimental autoimmune myasthenia gravis (EAMG). EAMG mice model was established by subcutaneous injection of synthetic analogue of acetylcholine receptor (AchR), then, hMSC were intravenously delivered into these mice repeatedly. The results showed that hMSC could specifically home to spleen tissue and hMSC treatment significantly improved the functional deficits of EAMG mice. In addition, AchR antibody level was dramatically decreased in cell-treated group when compared with untreated control on 10 days after the second cell injection. Moreover, both in vivo and in vitro mixed lymphocyte proliferation assays revealed that hMSC could definitely inhibit the proliferation of AchR-specific lymphocyte. In conclusion, our study demonstrated that hMSC treatment was therapeutically useful in autoimmune myasthenia gravis mice, and the underlying mechanism may relate with their immunomodulatory potential.
Yu
J
J
State Key Laboratory of Experimental Hematology, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union, Medical College (CAMS&PUMC), Tianjin, PR China.
Zheng
C
C
Ren
X
X
Li
J
J
Liu
M
M
Zhang
L
L
Liang
L
L
Du
W
W
Han
Z Chao
ZC
D000818:Animals; D000906:Antibodies / Q000097:blood / Q000276:immunology; D015703:Antigens, CD / Q000378:metabolism; D001835:Body Weight; D001854:Bone Marrow Cells / Q000166:cytology*; D002448:Cell Adhesion / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D019070:Cell Lineage; D049109:Cell Proliferation / Q000187:drug effects; D018920:Coculture Techniques; D003208:Concanavalin A / Q000494:pharmacology; D017077:Culture Media, Conditioned / Q000494:pharmacology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000494:pharmacology; D005260:Female; D006801:Humans; D056747:Immunomodulation; D016130:Immunophenotyping; D007275:Injections, Intravenous; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008221:Lymphoid Tissue / Q000166:cytology; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D011950:Receptors, Cholinergic / Q000276:immunology; D013154:Spleen / Q000166:cytology; D014183:Transplantation, Heterologous; D016896:Treatment Outcome
D000906:Antibodies; D015703:Antigens, CD; D017077:Culture Media, Conditioned; D018984:Epitopes, T-Lymphocyte; D011950:Receptors, Cholinergic; D003208:Concanavalin A